The Y-box binding protein-1 (YB-1) transcription factor is associated with unfavorable clinical outcomes. However, the mechanisms underlying this association remain to be fully elucidated. We demonstrate that YB-1 phosphorylation, indicative of YB-1 activation, is a powerful marker of outcomes for ovarian cancer patients. In ovarian cancer, YB-1 phosphorylation is induced by activation of the lysophosphatidic acid (LPA) receptor (LPAR) via SRC-dependent transactivation of the epidermal growth factor receptor (EGFR) that is coupled to MAPK/p90 ribosomal S6 kinase (p90RSK), but not phosphatidylinositol 3-kinase (PI3K)/AKT signaling. Activation of the LPAR/SRC/EGFR/MAPK/p90RSK/YB-1 axis leads to production of the EGFR ligand amphiregulin (AREG). AREG induces ongoing YB-1 phosphorylation as well as YB-1-dependent AREG expression, thus constituting an AREG/YB-1 self-reinforcing loop. Disruption of transactivation of the EGFR and the downstream self-reinforcing loop decreases invasiveness of ovarian cancer cells in vitro and limits ovarian cancer growth in xenograft models. These findings established the regulation and significance of YB-1 phosphorylation, therefore further exploration of this signaling axis as a therapeutic avenue in ovarian cancer is warranted.
INTRODUCTION
Ovarian cancer is the fifth leading cause of cancer death in women. In 2013 and in the United States alone, a total of 22 240 new cases are expected with B70% of the patients (14 030 cases) expected to die of their disease. 1 This abysmal outcome is due to delayed diagnosis accompanied with extensive metastasis and limited response to therapy. 2 Unfortunately, genomic characterization reported so far has failed to identify frequent targets for high-grade serous ovarian cancers other than TP53 and the homologous recombination pathway. [3] [4] [5] Therefore, further studies are needed to identify new therapeutic targets in ovarian cancer.
Studies from our laboratory and others have identified LPA (1-acyl-2-lyso-sn-glycero-3-phosphate) as a key growth factor in ascitic fluid, which reflects the microenvironment for ovarian cancer cell growth. 6, 7 LPA is produced in proximity to the tumor cell, in which lysophosphatidylcholine is hydrolyzed by cellassociated autotaxin. 8, 9 The resulting LPA binds to cell-surface G-protein-coupled LPA receptors (LPARs) to promote cancer cell functions. 10 Importantly, enforcing the expression of the LPA2 or LPA3 receptors enhances tumorigenicity and aggressiveness of ovarian cancer cells, 11 suggesting that LPA contributes to the pathophysiology of ovarian cancer through an autocrine LPA signaling loop.
The YB-1 transcription factor has emerged as a promising therapeutic target owing to its association with advanced tumor grades and unfavorable outcomes in multiple cancer lineages. 12 In ovarian cancer patients, nuclear YB-1 is associated with poor outcomes and resistance to chemotherapy. [13] [14] [15] Particularly, YB-1 phosphorylation at serine-102 regulates nuclear translocation and functional outcomes of YB-1. 16, 17 However, the clinical relevance of elevated phospho-YB-1 levels remains unknown. Moreover, the mechanism underlying YB-1 phosphorylation is not well understood. Interestingly, YB-1 was found to promote growth and aggressiveness of human mammary epithelial cells via constitutive activation of the EGFR pathway, 18 suggesting that the association of YB-1 with poor outcomes could be due to autocrine regulation of growth factors.
In this study, we employed an integrated approach to determine the significance of YB-1 and its regulation by growth factors in ovarian cancer. Our results reveal YB-1 as a convergent hub for LPA and EGF signaling via EGFR transactivation. We provide further evidence for an unexpected model, wherein YB-1 phosphorylation initiates a self-reinforcing loop involving production and release of the EGFR ligand, AREG, leading to further phosphorylation and activation of YB-1. The crosstalk and selfreinforcing loop are required for LPA-induced invasion of ovarian cancer cells. Further, an intact LPAR/EGFR/YB-1/AREG cascade is required for LPA-induced tumor growth in vivo.
RESULTS

YB-1 levels and phosphorylation status correlate with poor outcome of ovarian cancer patients
We began the study by establishing an association between YB-1 and patient outcomes in ovarian cancer. Our analyses from two independent ovarian cancer data sets (see Materials and methods for sample information) revealed that expression of YBX1 mRNA was significantly upregulated in ovarian cancers compared with normal tissues from The Cancer Genome Atlas (TCGA) data set (http://cancergenome.nih.gov), as well as in malignant compared with low malignant potential tumors from Bowtell data set 19 ( Figure 1a ). We next explored correlations between YB-1 and clinical outcomes using the same data sets. As expected, patients with high levels of YBX1 mRNA (on the basis of the lowest P-value of the log-rank test) had shorter relapse-free survival times 19 ( Figure 1b) . Strikingly, high levels of phospho-YB-1 strongly predicted a poor outcome for ovarian cancer patients, with Kaplan-Meier curves show the relapse-free or overall survival durations among ovarian cancer patients with low and high levels of YBX1 expression (YBX1 low , n ¼ 162 and YBX1 high , n ¼ 113, left panel) and levels of phospho-YB-1 (p-YB-1 S102 low , n ¼ 131 and p-YB-1 S102 high , n ¼ 201, right panel). The survival data for YBX1 expression levels in b were censored at 84 months, and P-values are indicated for all panels. Eight ovarian cancer cell lines (c) and cancer cell lines of other lineages as well as non-transformed mammary epithelial MCA10A cells (d) were treated with LPA (10 mM), EGF (10 ng/ml) or IGF-1 (10 ng/ml) for 1 h and western blot was performed. Band intensities of phospho-YB-1 (p-YB-1 S102 ), phospho-p90RSK (p-p90RSK T359/S363 ), phospho-AKT (p-AKT S473 ), YB-1, RSK1 and AKT were quantified and normalized to the intensity of ERK2. Micrographs are representative of three independent preparations. AREG/YB-1 self-reinforcing loop in ovarian cancer N Panupinthu et al almost half of the patients with low phospho-YB-1 surviving for more than 5 years (Figure 1b , TCGA data set). Total YB-1 protein levels and outcomes (P ¼ 0.11, analyzed from patients with low versus high levels of YB-1) were not correlated potentially due to effects of phosphorylation on post-translational stability or low antibody quality. These results make phospho-YB-1 as one of the strongest outcome predictors for ovarian cancer patients yet identified, and thus prompted us to investigate the regulation and consequences of YB-1 phosphorylation.
YB-1 is a target of growth factor stimulation in cancer cells To investigate the regulation of YB-1 phosphorylation, we examined the effects of three critical growth factors LPA, EGF and insulin-like growth factor 1 (IGF-1) using a panel of ovarian cancer cell lines (Supplementary Table 1 ). In most of the cell lines, LPA (3.91 ± 0.50-fold) and EGF (5.59 ± 0.89-fold) markedly increased YB-1 phosphorylation (Figure 1c) . IGF-1 (1.65±0.32-fold) only modestly induced YB-1 phosphorylation in a subset of these lines. This was not due to a lack of response to IGF-1 as evidenced by marked increase in AKT phosphorylation (Figure 1c ). These growth factors had no overt effects on total YB-1 levels within 1 h stimulation ( Figure 1c ) and, for LPA and EGF, up to 24 h in CAOV3 and SKOV3 cells (Supplementary Figure 1) . We next explored the generalizability of growth factor-induced YB-1 phosphorylation across tumor lineages (Supplementary Table 1) . Likewise, LPA (3.71 ± 0.72-fold) and EGF (7.09 ± 2.57-fold) markedly induced YB-1 phosphorylation, whereas IGF-1 (1.24 ± 0.25-fold) had little effect (Figure 1d ). Together, these data indicate that YB-1 is a target of LPAR and EGFR activation.
Mechanisms underlying growth factor-induced YB-1 phosphorylation Previous studies have proposed p90RSK (readout of RAS/ MAPK pathway activation) and AKT as potential regulators of YB-1 phosphorylation. 13 We found that LPA, EGF and IGF-1 had markedly different effects on p90RSK and AKT phosphorylation across cell lineages (Figures 1c and d) . LPA induced phosphorylation of p90RSK (2.13 ± 0.18-fold) and AKT (1.74 ± 0.32 fold). EGF also induced phosphorylation of p90RSK (3.17 ± 0.40-fold) and AKT (3.71±0.99-fold). IGF-1 markedly activated AKT (5.39±1.86 fold), however, it did not alter phosphorylation of p90RSK (1.01 ± 0.11 fold). These growth factors did not detectably alter total RSK1 and AKT levels within 1 h stimulation. As IGF-1 was ineffective on p90RSK and YB-1 phosphorylation, we postulated the dominant role of RAS/MAPK/p90RSK cascade in YB-1 regulation. Consistently, LPA efficiently induced YB-1 but not AKT phosphorylation in cell lines such as CAOV3, OVCAR5, CAL27, DU145 and HCC1954 (Figures 1c and d) . In addition, the correlation of phospho-YB-1 with phospho-p90RSK induced by EGF (Spearman's r ¼ 0.54, P ¼ 0.03) was significantly greater than that with phospho-AKT (Spearman's r ¼ À 0.06, P ¼ 0.81) analyzed from all cell lines.
Next, we used high-throughput and unbiased reverse phase protein arrays (RPPA) to identify correlations between YB-1 phosphorylation and activation of signaling pathways. SKOV3 cells, which produce and express modest levels of endogenous LPA and LPARs, 20, 21 were stimulated with exogenous LPA over a detailed time course. Importantly, the time course of YB-1 phosphorylation correlated with p90RSK ( Figure 2a , Cluster 2) but not AKT phosphorylation. YB-1 phosphorylation also temporally paralleled that of RB, S6, p70S6K and BAD downstream of the MAPK and/or AKT pathways depending on the ligands and cellular context. 22, 23 The timedependent effects of LPA on YB-1 phosphorylation were confirmed by western blotting in SKOV3 cells (Supplementary Figure 1) . The relatively high basal YB-1 phosphorylation in SKOV3 cells could be due to constitutive activation of LPAR. 20, 21 To determine whether MEK and p90RSK activation were required for YB-1 phosphorylation, we developed an additional RPPA data set using CAOV3 cells treated with inhibitors of MEK1/2, GSK1120212 24 and RSK1/2, SL0101. 25 GSK1120212 abolished LPA-and EGF-induced phosphorylation of p44/42MAPK, p90RSK and S6 at 1 h stimulation, establishing these proteins as being downstream of MEK1/2 upon stimulation ( Figure 2b ). SL0101 selectively inhibited the effects of LPA and EGF on phosphorylation of S6 but not on phosphorylation of p90RSK itself or the upstream p44/42MAPK. Importantly, inhibition of MEK1/2 or RSK1/2 suppressed both LPA-and EGF-induced YB-1 phosphorylation as shown by RPPA (Figure 2b ) or western blotting (Supplementary Figure 2) . Thus, YB-1 phosphorylation requires an intact MEK/p44/42MAPK/p90RSK pathway.
We directly determined the role of AKT using two potent AKT inhibitors with distinct actions-a catalytic domain inhibitor, GSK690693, 26 and an allosteric inhibitor, MK2206 27 -in UPN and SKOV3 cells, which showed appreciable AKT and YB-1 phosphorylation upon growth factor stimulation (Figures 1c and 2c and Supplementary Figure 3 ). GSK690693 increased basal and growth factor-induced AKT phosphorylation due to blocking a negative feedback loop downstream of AKT, whereas MK2206 abolished both basal and growth-factor-induced AKT phosphorylation. 28 Inhibition of the AKT pathway modestly decreased S6 phosphorylation compatible with a predominant role of the MAPK pathway and subsequent downstream activation (see Figure 2b) . Strikingly, neither GSK690693 nor MK2206 altered YB-1 phosphorylation induced by LPA or EGF in UPN ( Figure 2c ) and SKOV3 cells (Supplementary Figure 3) .
We used cell lines lacking AKT to further examine the effects of LPA and EGF on YB-1 phosphorylation. Deletion of AKT1 and AKT2, the only AKT isoforms expressed in DLD1 and HCT116 colon cancer cells, 29 resulted in a complete loss of AKT and phospho-AKT under basal and activation conditions ( Figure 2d ). However, both LPA and EGF could induce YB-1 phosphorylation in these cells. Together, the data argue that YB-1 phosphorylation is dependent on LPA-or EGF-induced activation of the p44/ 42MAPK/p90RSK pathway and not AKT.
LPA rapidly induces activation of the p44/42MAPK/p90RSK/YB-1 pathway via SRC-mediated crosstalk with the EGFR Our RPPA analyses suggested that LPA could activate receptor tyrosine kinases including the EGFR (tyrosine-992 and -1173 phosphorylation), HER2 and IGF1R (Figure 2a ). Given the inability of IGF-1 to induce YB-1 phosphorylation, we thus focused on the role of crosstalk between LPAR and the EGFR/ERBB family. Using an EGFR/ERBB phosphorylation array, we found that LPA induced EGFR phosphorylation at tyrosine-845 (approximately twofold, site not present on the RPPA platform) in CAOV3 cells, but not phosphorylation of other ERBB receptors including HER2 (Figure 3a) . LPA also induced EGFR phosphorylation at tyrosine-845, a likely SRC target site, in SKOV3 cells (see Figure 3f , below) consistent with the role of SRC in LPA-induced EGFR transactivation. 30 The discrepancy on HER2 phosphorylation between this array and RPPA is likely due to the greater sensitivity of RPPA.
We next examined the EGFR as a putative link between LPAR and YB-1. Indeed, gefitinib, which is selective for EGFR 31 and lapatinib, which inhibits EGFR and HER2, 32 abolished not only EGFbut also LPA-induced activation of the p44/42MAPK/p90RSK/YB-1 pathway (Figure 3b In another set of RPPA, CAOV3 cells were treated with GSK1120212 (1 mM) or SL0101 (100 mM) for 1h, followed by LPA (10 mM) or EGF (10 ng/ml) for another 1 h. Data are means±s.e.m. of triplicate samples. (c) UPN cells were treated with GSK690693 or MK2206 (1 mM) for 1h, followed by LPA (10 mM), EGF or IGF-1 (10 ng/ml) for another 1h and western blot was performed. Band intensities of phospho-AKT (p-AKT S473 ), phospho-S6 (p-S6 S240/S244 ), phospho-YB-1 (p-YB-1 S102 ) and YB-1 were quantified and normalized to the intensity of ERK2. (d) DLD1 and HCT116 cells (wild-type and AKT1/2 À / À ) were treated with LPA (10 mM), EGF or IGF-1 (10 ng/ml) for 1h and western blot was performed. Band intensities of AKT, p-AKT S473 , p-YB-1 S102 and YB-1 were quantified and normalized. Micrographs are representative of three independent preparations. AREG/YB-1 self-reinforcing loop in ovarian cancer N Panupinthu et al activation initiates a crosstalk with the LPAR in ovarian cancer cells. 34 We ruled out this possibility as Ki16425, an LPAR1/3 antagonist, 35 selectively suppressed LPA but not EGF effects on the p44/42MAPK/p90RSK/YB-1 pathway (Figure 3d ).
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We also demonstrated crosstalk between LPAR and EGFR in SKOV3 cells, in which activation of the p44/42MAPK/p90RSK/YB-1 pathway by EGF and LPA was inhibited by gefitinib or lapatinib ( Figure 3e ). As a site for SRC phosphorylation, 36 LPA-induced EGFR (p-p90RSK) and phospho-YB-1 S102 (p-YB-1) were quantified and normalized to the intensity of ERK2. Micrographs are representative of three independent preparations. (b) Eight ovarian cancer cells were treated with LPA (10 mM) for 24 h. Supernatants were collected and levels of AREG were assessed. ND ¼ not determined. (c) CAOV3 cells were treated with cycloheximide (10 mM) for 1 h followed by LPA (10 mM) for another 8 h, and levels of amphiregulin were assessed. (d) CAOV3 cells were treated with LPA (10 mM) or AREG (10 ng/ml) as times indicated and realtime RT-PCR was performed. (e) CAOV3 cells were treated with mAb for AREG (50 mg/ml, left panel) or gefitinib (1 mM, right panel) for 1 h followed by LPA as times indicated and western blot was performed. Band intensity of phospho-YB-1 (p-YB-1 S102 ) was quantified and normalized. Changes of p-YB-1 S102 /ERK2 ratios are normalized to ratio of the vehicle-treated cells at start (t ¼ 0). CAOV3 cells were treated with dasatinib, gefitinib or GSK1120212 (1 mM) for 1 h followed by LPA (10 mM, f ), EGF (10 ng/ml, g) for another 8 h and levels of AREG were assessed. Data are means±s.e.m, n ¼ 3 independent preparations, *Po0.05 compared with Control, t ¼ 0 or LPA þ vehicle and # Po0.05 compared with vehicle. AREG/YB-1 self-reinforcing loop in ovarian cancer N Panupinthu et al LPA induces delayed AREG release that initiates a self-reinforcing loop of YB-1 phosphorylation and subsequent AREG production Activation of SRC by GPCRs can lead to EGFR transactivation via rapid shedding of EGFR ligands from the cell surface. 38 We tested this possibility, in which shedding of EGFR ligands (AREG, EGF and transforming growth factor-a or TGFa) contributed to LPAinduced YB-1 phosphorylation. As expected, EGFR ligands strongly induced phosphorylation of the p44/42MAPK/p90RSK/ YB-1 pathway, which was abrogated by the neutralizing antibodies (Figure 4a) . However, none of the antibodies altered the initial phase of LPA-induced phosphorylation of the p44/ 42MAPK/p90RSK/YB-1 pathway, at the 1 h time point assessed. It is likely that the initial step in LPA-induced EGFR transactivation does not involve shedding of these EGFR ligands but is rather due to SRC activation.
LPA promotes release of cytokines and angiogenic factors from ovarian cancer cells, 11, 21 which may include ligands for EGFR family members. In contrast to the initial signaling events, production of these EGFR ligands could contribute to the delayed phase of EGFR activation (see Figure 2a) . We first examined the levels of three EGFR ligands in supernatants of ovarian cancer cell lines. These cell lines constitutively released AREG (except HEY cells) and lower levels of TGFa (P ¼ 0.112; AREG vs TGFa) but surprisingly not EGF (Supplementary Figure 5) . Within 24 h of addition, LPA increased AREG levels in the supernatants of several cell lines, reaching statistical significance in CAOV3, OV2008 and SKOV3 cells (Figure 4b ) consistent with the delayed EGFR and prolonged YB-1 activation of these cells. LPA did not induce EGF or increase TGFa release (Supplementary Figure 6) . The delayed release of AREG induced by LPA could be due to upregulation of AREG expression. Indeed, AREG release induced by LPA was markedly reduced by cycloheximide, an inhibitor of mRNA translation (Figure 4c) . Further, LPA massively induced AREG mRNA expression (Figure 4d ). Unexpectedly, we also found that exogenous AREG induced AREG mRNA expression consistent with LPA, initiating a self-reinforcing loop involving production and release of AREG, which in turn upregulates its own production.
It is plausible that the newly produced AREG initiates the delayed component of biphasic EGFR activation and contributes to prolonged YB-1 activation induced by LPA. Indeed, the AREG neutralizing antibody significantly suppressed delayed YB-1 phosphorylation from 4 to 24 h following LPA addition, whereas it had no effect within the first 2 h (Figure 4e ). In contrast, both initial and delayed effects were completely inhibited by gefitinib in keeping with the requirement of LPAR/EGFR crosstalk for initial activation of YB-1. AREG release by LPA but not EGF was sensitive to SRC inhibition, whereas AREG release by both LPA and EGF was sensitive to EGFR and MEK1/2 inhibition (Figures 4f and g ). These data suggest that YB-1 phosphorylation and AREG release by LPA involve two phases of EGFR activation, and the delayed AREG release is required for prolonged activation of the p44/42MAPK/ p90RSK/YB-1 pathway.
YB-1 is critical for LPA-induced AREG release and cell invasion through the EGFR crosstalk and activation of the p44/42MAPK/ p90RSK pathway We then asked whether the AREG autoregulatory loop was dependent on YB-1 activation by examining the role of YB-1 in cytokine production. LPA induced at least a twofold increase in levels of AREG, glial cell line-derived neurotrophic factor, coagulation factor III and CD26 but not EGF and HB-EGF in supernatants assessed by cytokine array (Figure 5b and  Supplementary Table 2 ). Importantly, YBX1 knockdown markedly decreased LPA-induced AREG release as assessed using the array and confirmed using ELISA (Figure 5c ). These findings suggest a self-reinforcing loop of AREG and YB-1, in which AREG is released initially upon YB-1 phosphorylation and subsequently acts as a mediator of YB-1 phosphorylation.
LPA and EGF are critical mediators of cell mobility and invasion. We thus explored the role of YB-1 in cell invasion. YBX1 knockdown significantly inhibited LPA-induced invasion of SKOV3 cells (Figure 5d ). Further, inhibition of the EGFR abolished both EGF-and LPA-induced invasion of SKOV3 cells (Figure 5e ), supporting the importance of the proposed signaling pathway. The effects of LPA and EGF on cell invasion were also sensitive to MEK1/2 and RSK1/2 but not AKT inhibition ( Supplementary  Figures 7 and 8) in keeping with the role of p44/42MAPK/ p90RSK pathway in YB-1 phosphorylation. Together, our data consistently indicate that activation of YB-1 through LPAR/EGFR crosstalk and the p44/42MAPK/p90RSK pathway contributes to functional outcomes including AREG release and ovarian cancer cell invasion (Figure 5f ).
The EGFR crosstalk and AREG/YB-1 self-reinforcing loop mediate LPA-induced tumor growth and invasiveness in vivo We found that high levels of EGFR expression predicted a worsened outcome using the TCGA data set (P ¼ 0.0059, Supplementary Figure 9 ) compatible with the EGFR being a therapeutic target in ovarian cancer. There was no significant correlation between LPAR2 levels and survival in this data set (P ¼ 0.15, Supplementary Figure 9 ). However, we have shown that ectopic expression of LPAR enhances growth of SKOV3 cells through an autocrine LPA signaling loop.
11 Therefore, we further evaluated the significance of the proposed signaling pathway using a xenograft model with enforced LPAR2 expression in SKOV3 cells (SKOV3-LPAR2). Indeed, SKOV3-LPAR2 tumors demonstrated significantly greater weight of tumors attached to abdominal organs, omentum, peritoneum and abdominal wall compared with those of b-galactosidase-expressing SKOV3 cells (SKOV3-LacZ) as control (Figure 5g ). Inhibition of LPAR/ EGFR crosstalk with gefitinib markedly decreased the growth of SKOV3-LPAR2 tumors, with the weights of treated tumors being comparable to those of SKOV3-LacZ tumors. Histopathological analysis of these tumors also revealed a significant decrease in tumor invasiveness in animals treated with gefitinib (Supplementary Figure 10) . Importantly, mice bearing SKOV3-LPAR2 tumors also showed elevated serum AREG with increased phosphorylated YB-1 levels in the tumors (Figures 5h and i) . These increases were also effectively blocked by gefitinib. Therefore, these findings recapitulate the signaling pathway developed in vitro, wherein LPA induces EGFR transactivation leading to YB-1 phosphorylation and subsequent AREG production in ovarian tumors.
DISCUSSION
In this study, we have uncovered the regulation and function of YB-1 in ovarian cancer using clinical data, high-throughput arrays with complementary biochemical methods and an ovarian xenograft model. We reveal here that YB-1 is a novel and generalized target of LPA and EGF signaling across cancer types. Further, high levels of phospho-YB-1, presumably due to activation of growth factor signaling, are associated with poor outcomes in ovarian cancer patients. These further establish YB-1 as a critical oncogenic factor that drives aggressiveness of tumors in human and mice as previously proposed in breast cancer. 39 Our study points to an increase in ovarian cancer cell invasiveness as a potential cause of the worsened outcomes concordant with an increase in metastatic potential of breast cancer cells observed with overexpression of YB-1. 40 In ovarian cancer, increased nuclear expression of YB-1 is also associated with outcomes and the resistance to chemotherapy. 13, 15 Therefore, our present study uncovers the mechanism and significance of YB-1 AKT and p90RSK were proposed to phosphorylate YB-1 in basal breast cancer cell lines. 16 However, the mechanisms by which these kinases regulate YB-1 were not well defined. Here, we provide conclusive evidence that LPA-and EGF-induced YB-1 phosphorylation are predominantly regulated via the p44/ 42MAPK/p90RSK pathway and not the AKT pathway in the broad range of cells studied. The p44/42MAPK/p90RSK pathway coordinates functional outcomes including AREG production and cell invasion in our study as well as gene expression in colorectal cancer cells. 41 Targeting this pathway may have a therapeutic implication as implicated in the xenograft model of ovarian cancer and triple-negative breast cancer. 42 Although our data excluded the involvement of AKT, AKT has been proposed in nuclear translocation of YB-1 and associated with aggressiveness of ovarian cancer cells. 13 It is possible that there is an alternative and yet unidentified AKT-dependent pathway that regulates YB-1 nuclear localization in ovarian cancer.
YB-1 has been proposed to support tumor growth through activation of EGFR signaling independent of exogenous EGF. 18, 43 Indeed, present study reveals a plausible mechanism of EGFR autoregulation specifically via AREG production. Endogenous AREG can form a self-reinforcing loop of YB-1 activation and further production of AREG. The significance of the autoregulation has been shown, wherein AREG acts as an essential autocrine growth factor that promotes growth of mammary tumors. 44, 45 Our data also revealed that ovarian cancer cell lines constitutively produce AREG at higher levels compared with EGF and TGFa, suggesting that AREG is a critical and relevant EGFR ligand that promotes ovarian cancer progression.
In the proposed signaling pathway, EGFR activation occurs through two distinct and temporally independent mechanisms, an initial transactivation induced by SRC followed by delayed activation of the EGFR through YB-1-dependent upregulation of AREG. Although we found perviously that SRC-mediated shedding of AREG to be the underlying mechanism of EGFR crosstalk in head-and-neck cancer cells, 38 the initial phase of EGFR crosstalk was found to be dependent on SRC but independent of AREG shedding in ovarian cancer cells. Thus, crosstalk between GPCRs (LPAR in ovarian cancer and gastrin-releasing peptide receptor in head-and-neck cancer) and receptor tyrosine kinases (EGFR) can occur through diverse mechanisms as previously proposed. 46 The delayed production of AREG may explain the need for prolonged exposure to LPA, and consequent SRC-mediated EGFR phosphorylation and p42/44 MAPK activation to induce DNA synthesis and cellular proliferation. 47, 48 In addition, we have reported that LPAR/EGFR transactivation enhances MMP-9 expression and invasiveness of ovarian cancer cells via the RAS/ Rho/ROCK/NF-kB pathway. 49 It is possible that both phases of EGFR activation are required for LPA-induced ovarian tumor growth and invasion as observed in ovarian xenograft tumors driven by LPA2 receptors. Interestingly, our preliminary data in SKOV3 cells suggested that MMP-9 release induced by LPA was decreased when YBX1 was depleted (Supplementary Table 2 ). Therefore, ongoing AREG/YB-1 autoregulation may be required to maintain functional EGFR activation. Although we have revealed the pathway that initiates AREG/YB-1 self-reinforcing loop, the mechanism by which this loop is terminated remains to be ascertained. It likely involves an induction of phosphatases such as the dual specific phosphatases, which are components of negative feedback pathway that regulates EGFR/MAPK activation. 50 LPA receptors represent potential therapeutic targets with a number of approaches being under investigation, 51 and several EGFR inhibitors have already been approved for use, albeit with limited activity as a single agent. Inhibition of GPCRs or SRC can increase the sensitivity of tumor cells to anti-EGFR targeted therapy, 52, 53 potentially by interrupting the crosstalk and selfreinforcing AREG loop. However, the limited effects of the EGFR inhibitors in ovarian cancer should be interpreted with caution, as resistance can occur rapidly and limit the efficacy. 54 On the basis of our current work, the mechanisms of resistance could involve the initiation of the AREG/YB-1 self-reinforcing loop. Indeed, resistance to gefitinib could be overcome by knockdown of AREG. 55 Our data also argue that YB-1 is an interesting therapeutic target as it acts as an integration point of EGFR activation via crosstalk and autoregulation. In this regard, small molecules targeting YB-1 phosphorylation have been developed 56 and could alleviate resistance to EGFR therapy. In summary, there are a number of plausible regimens targeting multiple steps of an important signaling pathway for the pathophysiology of ovarian cancer that might improve outcomes in patients. These coordinate inhibition approaches may demonstrate favorable efficacy, and thus warrant further exploration.
MATERIALS AND METHODS
Cell lines and reagents
Ovarian, prostate and breast cancer cell lines and MCF10A cells were from the Characterized Cell Line Core Facility of the MD Anderson Cancer Center. Head-and-neck cancer cell lines were from ATCC (Manassas, VA, USA). Lung cancer cell lines were from Dr John Heymach at MD Anderson Cancer Center. Colon cancer cells were from Dr Bert Vogelstein at Johns Hopkins Kimmel Cancer Center. Cell lines were authenticated by STR screening and confirmed to be mycoplasma negative by the Cell Line Core Facility and maintained in a complete medium (RPMI-1640 or DMEM containing 5% fetal bovine or horse serum). IGF-1, EGFR ligands and the neutralizing antibodies were from R&D Systems (Minneapolis, MN, USA). LPA (1-oleoyl-2-hydroxy-sn-glycero-3-phosphate) and Ki16425 were from Avanti Polar Lipids Inc (Alabaster, AL, USA). Cetuximab and Trastuzumab were from pharmacy at the MD Anderson Cancer Center. GSK1120212 was obtained under a material transfer agreement with GlaxoSmithKline (Boston, MA, USA). SL0101 was from EMD Millipore (Billerica, MA, USA). Gefitinib and lapatinib were from LC Laboratories (Woburn, MA, USA). GSK690693, MK-2206 and dasatinib were from Selleck Chemicals LLC (Houston, TX, USA). Growth factors were prepared in phosphate buffered saline containing 1 mg/ml of fatty acid-free bovine albumin. All inhibitors were dissolved in dimethyl sulfoxide.
Data sets of ovarian cancer patients
Two ovarian cancer patient data sets (TCGA and Bowtell data sets) were included in the analyses without the restriction of stage or age. In TCGA data set, YBX1 expression was analyzed from 519 ovarian serous cystadenocarcinoma samples and 8 unmatched normal ovarian tissue samples. There were 332 serous cystadenocarcinoma samples with matched RPPA data and outcomes. These samples were from patients with stage II (5.1%), stage III (80.4%) and stage IV (14.9%) tumors, and age range of 27.2 to 84.7 years. In the Bowtell data set, 267 samples were characterized as high-grade, late-stage serous ovarian tumors and 18 samples were characterized as low-grade, early-stage ovarian tumors with low malignant potential. For further information, see Table 1 of the original paper by Tothill and coworkers. 19 Antibody arrays, western blot analyses and ELISA RPPA was performed in triplicate samples of CAOV3 and SKOV3 cells as described previously. 57 Heat map with hierarchical clustering using the normalized levels of phospho-proteins was obtained using Cluster 2.11 (http://www.eisenlab.org/eisen). 58 Western blots were performed as previously described. 11 All antibodies are listed in Supplementary  Table 3 . We assessed EGFR/ERBB phosphorylation profile using human EGFR phosphorylation antibody array (RayBiotech, Inc., Norcross, GA, USA). Production of cytokines was assessed using a human angiogenesis antibody array or DuoSet ELISA kits (R&D Systems). Band and spot intensities were quantified using AlphaView SA version 3.2.3.0 (ProteinSimple, Santa Clara, CA, USA). Transwell migration and invasion assay Cells were seeded on Matrigel-coated transwell invasion chambers with 8-mm pore size (BD Bioscience, San Jose, CA, USA) at 5 Â 10 4 cells in serumfree medium containing inhibitors. The chambers were then placed into each well of the 24-well plate containing serum-free medium with growth factors. After 24 h incubation, invasive cells were visualized using crystal violet and then counted.
Real-time RT-PCR
Real-time RT-PCR was performed using the ABI Prism 7900 HT Sequence Detector (Perkin-Elmer, Waltham, MA, USA), and samples were processed as described previously.
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The mouse xenograft model of SKOV3 cells overexpressing LPA2 receptors SKOV3 cells expressing lentiviral constructs carrying LPAR2 or LacZ gene were injected intraperitoneally into 6-week-old BALB/c Nu/Nu female mice as described previously. 11 In both groups, mice were randomly divided to receive gefitinib (100 mg/kg) or vehicle orally 1 week after tumor cell injection. The animals were then treated every 3 days for an additional 2 weeks and euthanized. Tumor burden was measured as a collective weight of all visible tumor nodules that were attached to the abdominal organs, omentum, peritoneum and abdominal wall. Protein from tumors was extracted for western blot . Blood samples were collected and serum levels of AREG were assessed using ELISA. Xenograft tumors collected from abdominal cavity of mice were fixed in 10% neutral buffered formalin and were processed into hematoxylin and eosin (H&E)-stained histologic sections as described previously. 11 A pathologist (MG) examined microscopically the H&E-stained sections of tumors and evaluated the invasiveness of the tumors according to the criteria for histopathologic grading score in Supplementary Table 4. All animal experimental procedures were conducted in compliance with the regulations of MD Anderson Cancer Center Institutional Animal Care and Use Committee.
